Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes

Published:2021-01-01 Issue:1 Volume:60 Page:15-23
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nakajima Hideaki¹

Affiliation:

1. Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/60/1/60_4214-19/_pdf

Reference74 articles.

1. 1. Ogawa S. Genetics of MDS. Blood 133: 1049-1059, 2019.

2. 2. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87: 515-526, 2008.

3. 3. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110: 4385-4395, 2007.

4. 4. Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS. Advances in the 5q- syndrome. Blood 116: 5803-5811, 2010.

5. 5. Bernasconi P, Klersy C, Boni M, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19: 1424-1431, 2005.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between gene mutations and certain blood cell indices in patients diagnosed with myelodysplastic neoplasms;World Academy of Sciences Journal;2024-03-22

2. O-GlcNAcylation: Implications in normal and malignant hematopoiesis;Experimental Hematology;2021-09